Redwood Investment Management LLC Purchases New Shares in West Pharmaceutical Services, Inc. $WST

Redwood Investment Management LLC purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,283 shares of the medical instruments supplier’s stock, valued at approximately $1,179,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $2,387,990,000. State Street Corp boosted its position in West Pharmaceutical Services by 2.1% during the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after purchasing an additional 68,330 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of West Pharmaceutical Services by 2.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after buying an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at about $733,733,000. Finally, Generation Investment Management LLP bought a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at about $728,168,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $350.68 on Thursday. The firm has a market cap of $24.68 billion, a PE ratio of 44.90, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The business’s fifty day simple moving average is $349.99 and its 200-day simple moving average is $302.68.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. West Pharmaceutical Services’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is 11.27%.

Wall Street Analyst Weigh In

Several research firms have weighed in on WST. Evercore reiterated an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Stephens reaffirmed an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Citigroup upped their target price on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Finally, BNP Paribas Exane started coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.